Kamada (KMDA) Liabilities and Shareholders Equity (2012 - 2026)
Kamada's (KMDA) quarterly Liabilities and Shareholders Equity came in at $383.0 million in Q1 2026, up 2.11% YoY from $375.1 million in Q1 2025, and up 1.14% on a QoQ basis from $378.7 million in Q4 2025.
Kamada (KMDA) Liabilities and Shareholders Equity (2012 - 2026) Analysis & Trends
Kamada (KMDA) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $383.0 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 2.11% year-over-year to $383.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 3.97% YoY) and the FY2025 annual result came in at $378.7 million, up 1.73% from the prior year.
- Liabilities and Shareholders Equity climbed to $383.0 million in Q1 2026, from $378.7 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $343.2 billion in Q1 2024 to a low of $303.1 million in Q1 2022.
- A 5-year average of $77.7 billion and a median of $372.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 147519.93% — and 2024, when it plunged 99.9%.
- Tracing KMDA's Liabilities and Shareholders Equity over 5 years: stood at $322.4 million in 2022, then rose by 10.09% to $354.9 million in 2023, then increased by 4.89% to $372.3 million in 2024, then increased by 1.73% to $378.7 million in 2025, then increased by 1.14% to $383.0 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $383.0 million (Q1 2026), $378.7 million (Q4 2025), and $377.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 6.18 Bn |
| 10 | Kamada | 465.93 Mn | 436.45 Mn | 22.47 Mn | 383.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 383.16 Mn |
| Mar 31, 2026 | 383.02 Mn |
| Dec 31, 2025 | 378.71 Mn |
| Sep 30, 2025 | 377.21 Mn |
| Jun 30, 2025 | 368.17 Mn |
| Mar 31, 2025 | 375.11 Mn |
| Dec 31, 2024 | 372.26 Mn |
| Sep 30, 2024 | 351.21 Mn |
| Jun 30, 2024 | 351.04 Mn |
| Mar 31, 2024 | 343.17 Bn |
| Dec 31, 2023 | 354.91 Mn |
| Sep 30, 2023 | 337.06 Bn |
| Jun 30, 2023 | 314.39 Mn |
| Mar 31, 2023 | 316.80 Bn |
| Dec 31, 2022 | 322.38 Mn |
| Sep 30, 2022 | 319.64 Bn |
| Jun 30, 2022 | 304.14 Mn |
| Mar 31, 2022 | 303.10 Mn |
| Dec 31, 2021 | 318.67 Mn |
| Sep 30, 2021 | 216.53 Mn |